---
document_datetime: 2024-11-21 15:40:18
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dapagliflozin-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: dapagliflozin-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.424119
conversion_datetime: 2026-01-29 11:50:06.391588
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dapagliflozin Viatris

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0004              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 20/11/2024                          |                                             | SmPC                             |           |
| IB/0003              | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                              | 26/07/2024                          | 05/08/2024                                  | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            | Labelling and PL                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0002   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                    | 19/03/2024 | 05/08/2024 | SmPC, Annex II, Labelling and PL |
| IAIN/0001 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                               | 17/01/2024 | 05/08/2024 | SmPC                             |